Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment

Summary

The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α + ribavirin (non-responders or relapsers).

Timeline

Start

2012-05

Primary completion

2014-12

Completion

2015-07

Drugs

Indications